Article
Cell Biology
Yinjiang Zhang, Hongyun Wei, Lu Fan, Mingyan Fang, Xu He, Binan Lu, Zongran Pang
Summary: The study found that CLEC4A and CLEC4L mRNA levels were significantly higher in HCC tissues compared to normal liver tissues, while CLEC4G/H1/H2/M expression levels were significantly lower. The expression of CLEC4H1 and CLEC4H2 was significantly associated with clinical stages, and the expression of other CLEC4s decreased with tumor progression.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Oncology
Jing Li, Xin Wang, Mudan Ren, Shuixiang He, Yan Zhao
Summary: Hepatocellular carcinoma (HCC) is a common malignant tumor with poor prognosis. Animal models play a crucial role in studying the pathogenesis and drug development for HCC. This review provides a comprehensive summary of the classification, characteristics, and advances in experimental animal models of HCC, serving as a reference for researchers in model selection.
Review
Biochemistry & Molecular Biology
Donghong Yuan, Yu Chen, Xiaobing Li, Jing Li, Yueshui Zhao, Jing Shen, Fukuan Du, Parham Jabbarzadeh Kaboli, Mingxing Li, Xu Wu, Huijiao Ji, Chi Hin Cho, Qinglian Wen, Wanping Li, Zhangang Xiao, Bo Chen
Summary: Long non-coding RNAs (lncRNAs) play crucial roles in the occurrence and progression of hepatocellular carcinoma (HCC), promoting various biological behaviors of tumor cells and serving as potential biomarkers to predict treatment efficacy and as personalized tools for diagnosis and treatment.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Review
Medicine, Research & Experimental
Risheng He, Zhongrui Wang, Wenguang Shi, Liang Yu, Haoming Xia, Ziyue Huang, Shuqiang Liu, Xudong Zhao, Yi Xu, Judy Wai Ping Yam, Yunfu Cui
Summary: This review explores the role of exosomes in HCC and emphasizes the impact of exosome-mediated cellular material transfer on HCC progression. The potential molecular mechanisms underlying these effects are discussed, with the hope of shedding new light on the diagnosis and treatment strategies for HCC.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Cell Biology
Selena Y. Lin, Adam Zhang, Jessica Lian, Jeremy Wang, Ting-Tsung Chang, Yih-Jyh Lin, Wei Song, Ying-Hsiu Su
Summary: The study identified 396 recurrently targeted genes (RTGs) in HBV-associated HCC, with 23 of them associated with carcinogenesis. Among the top three RTGs, TERT, MLL4/KMT2B, and PLEKHG4B were identified as most frequently targeted. Comprehensive analysis of these genes provides insights for potential drug development and disease management in HCC.
Article
Oncology
Zehua He, Qingfeng Chen, Wanrong He, Junyue Cao, Shunhan Yao, Qingqiang Huang, Yu Zheng
Summary: This study analyzed the metabolic heterogeneity of epithelial cells in hepatocellular carcinoma (HCC) and identified potential biomarkers. It found that the glycolytic subtype of HCC cells with high ALDOA expression is associated with an immunosuppressive tumor microenvironment and predicts worse clinical outcomes.
FRONTIERS IN ONCOLOGY
(2023)
Article
Materials Science, Multidisciplinary
Mahsa Sedighi, Zahra Mahmoudi, Samin Abbaszadeh, Mohammad Reza Eskandari, Morvarid Saeinasab, Farshid Sefat
Summary: Human hepatocellular carcinoma (HCC) is a significant cause of mortality globally. Extensive research has been conducted to understand the mechanisms involved in the disease's pathogenesis and develop innovative diagnostic and therapeutic strategies. Nanotechnology has great potential in HCC diagnosis and treatment through targeted delivery, ensuring sufficient doses in tumor areas without harming normal cells.
MATERIALS TODAY COMMUNICATIONS
(2023)
Review
Oncology
Dino Bekric, Matthias Ocker, Christian Mayr, Sebastian Stintzing, Markus Ritter, Tobias Kiesslich, Daniel Neureiter
Summary: In recent years, scientific discoveries have brought new breakthroughs in the treatment of hepatocellular carcinoma (HCC). Ferroptosis, as a novel form of cell death, may negatively impact HCC and serve as a potential anti-cancer strategy. Understanding the role of ferroptosis in HCC and its application in clinical practice is of great importance.
Article
Immunology
Yongbiao Huang, Ye Yuan, Sheng Chen, Duo Xu, Lingyan Xiao, Xi Wang, Wan Qin, Bo Liu
Summary: This study aimed to investigate the therapeutic effects and underlying action mechanisms of vitamin D in COVID-19 and HCC. Through bioinformatics and network pharmacology analyses, we identified target genes and analyzed their prognostic significance in HCC patients. We developed a risk score model to evaluate the prognosis of HCC patients with COVID-19 and identified seven potential pharmacological targets of vitamin D. We also revealed the biological functions, signaling pathways, and TF-miRNA coregulatory network of vitamin D in COVID-19/HCC.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell Biology
Miaomiao Liu, Zijin Zhao, Yuan Cai, Peng Bi, Qiuju Liang, Yuanliang Yan, Zhijie Xu
Summary: Hepatocellular carcinoma (HCC) is a common high malignancy with poor prognosis. The YTH domain family plays a critical role in the development and progression of HCC, with YTHDF1 being particularly significant. High levels of YTHDF1 and YTHDF2 are associated with shorter overall survival time in HCC patients, while low levels of YTHDF1 are linked to longer progression-free survival time. The YTH domain family is also connected to immune cell infiltration and various cancer-related pathways in HCC pathology, suggesting potential for YTH-targeted therapy.
Review
Oncology
Xiang-Yuan Luo, Kong-Ming Wu, Xing-Xing He
Summary: Hepatocellular carcinoma is a deadly health burden worldwide, but recent years have seen significant breakthroughs in new drug development. The FDA has approved multiple drugs for HCC treatment, with over 1000 ongoing clinical trials globally, indicating a vibrant atmosphere in the HCC drug research field.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Review
Pharmacology & Pharmacy
Dongming Li, Donghui Cao, Yingnan Cui, Yuanlin Sun, Jing Jiang, Xueyuan Cao
Summary: HCC is a deadly malignancy with a poor prognosis. EGCG, a natural polyphenol, has shown potential for preventing and inhibiting HCC through multiple biological mechanisms. It also enhances the efficacy and sensitivity of chemotherapy, radiotherapy, and targeted therapy in HCC.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Genetics & Heredity
Lei Zhou, Guojie Chen, Tao Liu, Xinyuan Liu, Chengxiao Yang, Jianxin Jiang
Summary: This study found that the aberrant expression of MJDs family members in hepatocellular carcinoma (HCC) is closely related to clinical features, prognosis, tumor microenvironment, and immune-related molecules. MJDs family may serve as effective immunotherapeutic targets and prognostic biomarkers for patients with HCC.
FRONTIERS IN GENETICS
(2022)
Review
Pharmacology & Pharmacy
Mario Manto, Jan Cendelin, Michael Strupp, Hiroshi Mitoma
Summary: There are multiple etiologies for cerebellar ataxias (CAs) and they exhibit high phenotypic variability. Despite progress in understanding the pathogenesis, there are limited therapeutic options available. This article focuses on preclinical models, cerebellar reserve, therapeutic management of CAs, and suitable surrogate markers. It discusses the need for preclinical studies, standardization of disease evaluation, safety assessment, and demonstration of clinical improvements in the development of therapies for CAs.
EXPERT OPINION ON THERAPEUTIC TARGETS
(2023)
Review
Biochemistry & Molecular Biology
Andrei Sorop, Diana Constantinescu, Florentina Cojocaru, Anca Dinischiotu, Dana Cucu, Simona Olimpia Dima
Summary: Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and is often detected late due to its high clinical and biological heterogeneity. Small nanoparticles with an endosomal origin are valuable biomarkers or carriers for novel treatments in HCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
